Synbio International Inc. (OTC: SYIN) announced approval for Deposit/Withdrawal at Custodian (DWAC) and Direct Registration System (DRS) processing through Pacific Stock Transfer Company. The company views this as a significant advancement in modernizing its trading infrastructure and broadening market access.
What DWAC and DRS Mean for Shareholders
DWAC enables electronic share transfers between broker-dealers and transfer agents, eliminating physical certificates, accelerating settlement, and reducing trading friction. DRS allows shareholders to maintain shares directly on the company’s books electronically, granting them enhanced control and ownership security without intermediaries.
“Achieving DWAC and DRS eligibility is a foundational step in strengthening Synbio’s capital markets platform,” said CEO Claudio Solitario.
Mr. Solitario emphasized the importance of accessible, tradable stock as the organization pursues financing activities and partnership development initiatives.
The company describes itself as focused on clinically validated, AI-driven medical diagnostics, working through strategic partnerships to bridge wellness and medicine. Synbio said it plans multiple near-term capital markets and operational catalysts.
This release may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding Synbio International Inc.’s business strategy, product development, clinical trial plans, and future operations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and readers should not place undue reliance on them. Synbio undertakes no obligation to update any forward-looking statement except as required by law.
For informational purposes only — this release is republished from the company’s official disclosures and public news distribution. Investors should refer to Synbio International’s filings on the Investors page and on OTC Markets for complete and current information.